Literature DB >> 11960817

Genetics of familial episodic vertigo and ataxia.

Robert W Baloh1, Joanna C Jen.   

Abstract

The familial episodic ataxias are prototypical inherited channelopathies that result in episodes of vertigo and ataxia triggered by stress and exercise. Episodic ataxia type 1 (EA-1) is caused by missense mutations in the potassium channel gene KCNA1, whereas episodic ataxia type 2 (EA-2) is caused by missense and nonsense mutations in the calcium channel gene CACNA1A. These ion channels are crucial for both central and peripheral neurotransmission. Within the last few years, the genetic mechanisms underlying these relatively rare familial episodic ataxia syndromes have been worked out. They provide a model for understanding the mechanisms of more common recurrent vertigo and ataxia syndromes, particularly those associated with migraine. Migraine affects as many as 15-20% of the general population, and it has been estimated that about 25% of patients with migraine experience spontaneous attacks of vertigo and ataxia. We identified 24 families with migraine and benign recurrent vertigo inherited in an autosomal dominant fashion. These families have numerous features in common with EA-1 and EA-2 (particularly EA-2), suggesting that benign recurrent vertigo may be an inherited channelopathy. An ion channel mutation shared by brain and inner ear could explain the combined central and peripheral features of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960817     DOI: 10.1111/j.1749-6632.2002.tb02832.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  Diagnostic value of nystagmus: spontaneous and induced ocular oscillations.

Authors:  A Serra; R J Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

Review 2.  Migraine-related vertigo: diagnosis and treatment.

Authors:  Scott D Z Eggers
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

3.  Acetazolamide: A New Treatment for Visual Vertigo.

Authors:  Ilya M Sluch; Michael S Elliott; Justin Dvorak; Kai Ding; Bradley K Farris
Journal:  Neuroophthalmology       Date:  2017-08-02

Review 4.  Calcium channelopathies.

Authors:  Ricardo Felix
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 4.103

Review 5.  Danger: High Voltage-The Role of Voltage-Gated Calcium Channels in Central Nervous System Pathology.

Authors:  Andrea Schampel; Stefanie Kuerten
Journal:  Cells       Date:  2017-11-15       Impact factor: 6.600

6.  Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update.

Authors:  Sergio Carmona; Osvaldo Bruera
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

Review 7.  Migraine-related vertigo: diagnosis and treatment.

Authors:  Scott D Z Eggers
Journal:  Curr Pain Headache Rep       Date:  2007-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.